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Abstract
Previous studies have reported elevated levels of biogenic aldehydes in the brains of patients with Parkinson’s disease (PD).
In the brain, aldehydes are primarily detoxified by aldehyde dehydrogenases (ALDH). Reduced ALDH1 expression in
surviving midbrain dopamine neurons has been reported in brains of patients who died with PD. In addition, impaired
complex I activity, which is well documented in PD, reduces the availability of the NAD
+ co-factor required by multiple ALDH
isoforms to catalyze the removal of biogenic aldehydes. We hypothesized that chronically decreased function of multiple
aldehyde dehydrogenases consequent to exposure to environmental toxins and/or reduced ALDH expression, plays an
important role in the pathophysiology of PD. To address this hypothesis, we generated mice null for Aldh1a1 and Aldh2, the
two isoforms known to be expressed in substantia nigra dopamine neurons. Aldh1a1
2/26Aldh2
2/2 mice exhibited age-
dependent deficits in motor performance assessed by gait analysis and by performance on an accelerating rotarod.
Intraperitoneal administration of L-DOPA plus benserazide alleviated the deficits in motor performance. We observed a
significant loss of neurons immunoreactive for tyrosine hydroxylase (TH) in the substantia nigra and a reduction of
dopamine and metabolites in the striatum of Aldh1a1
2/26Aldh2
2/2 mice. We also observed significant increases in
biogenic aldehydes reported to be neurotoxic, including 4-hydroxynonenal (4-HNE) and the aldehyde intermediate of
dopamine metabolism, 3,4-dihydroxyphenylacetaldehyde (DOPAL). These results support the hypothesis that impaired
detoxificationof biogenic aldehydesmaybeimportant inthepathophysiology ofPD andsuggest that Aldh1a1
2/26Aldh2
2/2
mice may be a useful animal model of PD.
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Introduction
Parkinson’s disease (PD) is the 2
nd most prevalent neurodegen-
erative disease. It is classically diagnosed by the presence of
movement and gait abnormalities, but also involves non-motor
features, including autonomic and cognitive manifestations [1].
Pathological hallmarks of PD include age-progressive degeneration
of mesencephalic dopamine neurons and, in surviving neurons, the
presence of Lewy bodies, cytoplasmic inclusions of which a-
synuclein is a major constituent [2]. Symptoms of PD areassociated
with loss of dopamine in the substantia nigra and striatum [3].
Mechanisms of PD pathogenesis remain to be elucidated.
Numerous studies have implicated mitochondrial dysfunction and
elevated oxidative stress [4]. In addition to genetic and
environmental factors that can contribute to oxidative stress and
mitochondrial dysfunction, excess biogenic aldehydes may also
play an important role [5]. Biogenic aldehydes are cytotoxic, can
cause protein cross-linking [6] and promote a-synuclein oligomer-
ization [7–9]. Elevated levels of 4-hydroxynonenal (4-HNE), the
end product of lipid peroxidation, have been reported in affected
brain regions of patients dying with PD and increased ratio of 3,4-
dihydroxyphenlyacetaldehdye (DOPAL), the first product of
dopamine metabolism by monoamine oxidase (MAO), relative
to dopamine have been reported in the brains of PD patients
[7,10,11].
Aldehyde dehydrogenases play an important role in detoxifying
aldehydes in the brain. There are 19 human aldehyde dehydro-
genase isoforms and 20 mouse isoforms with wide tissue
distribution and localization in all subcellular compartments,
including cytosol, mitochondria, endoplasmic reticulum, and
nucleus [12]. In the brain, Aldh1a1 (ALDH1 in humans), a
cytosolic enzyme, is highly and exclusively expressed in midbrain
dopaminergic neurons [13–15]. ALDH1 mRNA expression is
reportedly decreased in surviving neurons of PD patients [14,15].
Mitochondrial Aldh2, (ALDH2 in humans) is also expressed in
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of function genetic polymorphism (ALDH2*2) frequently found in
northeast Asians, has been identified as a risk factor for
Alzheimer’s disease [16–18]. In addition, impaired complex I
activity, a well-documented finding in PD, reduces the availability
of the NAD
+ co-factor required by multiple ALDH isoforms to
catalyze the removal of biogenic aldehydes. We hypothesized that
chronically decreased function of multiple aldehyde dehydroge-
nases consequent to exposure to environmental toxins and/or
reduced ALDH expression, plays an important role in the
pathophysiology of PD. To test this hypothesis, we created
mice with double homozygous mutations in Aldh1a1 and
mitochondrial Aldh2, the two isozymes known to be expressed in
midbrain dopamine neurons [13,14]. Loss of these two enzymes
resulted in decline in locomotor function, loss of tyrosine
hydroxylase (TH) immunoreactive neurons in the substantia nigra
pars compacta, and reductions in monoamines and metabolites in
the neostriatum.
Results
Effect of Genotype and Age on Grip Strength and Body
Weight
Figure 1A shows that there was no effect of genotype on body
weight (F1,176=2.605, p=0.108). However, there was a significant
effect of age on body weight (F2,176=6.527, p=0.002). There was
no interaction between genotype and age on body weight
(F2,176=1.213, p=0.30) Similarly in Figure 1B, there was no
effect of genotype on grip strength (F1,103=0.0357, p=0.850) in
Aldh1a1
2/26Aldh2
2/2 mice, but there was a significant effect of
age on grip strength (F2,103=5.558, p=0.015). There was no
interaction between genotype and age on grip strength
(F2,103=1.812, p=0.168). There were also no differences in tests
of general locomotor activities measured in an open field, a light/
dark open field activity test and in 24-hour activity tests (Figure S1).
Effect of Genotype and Age on Rotarod Performance
Figure 2 shows the results of measuring the effects of genotype
and age on motor performance on the accelerating rotarod. There
was a significant effect of age (F2,189=13.301, p,0.001) and
genotype (F1,189=29.351, p,0.001) on rotarod performance.
There was no statistically significant interaction between age and
genotype (F2,189=0.018, p=0.983). Student-Newman-Kuels post-
hoc comparison of individual means revealed significant differences
at each age between Aldh1a1
2/26Aldh2
2/2 mice and their age-
matched wild type controls. Thus, the Aldh1a1
2/26Aldh2
2/2
mice spent significantly less time on the rotarod than age-matched
wild type mice with a mean percentage reduction of 29% in the
young mice, 35% reduction in middle-aged mice and a 43%
decline in the mean latency to fall in the old mice as compared to
wild type mice of the same age.
Effect of Genotype and Age on Gait Performance
We then analyzed motor function by gait analysis in a subset of
animals. As shown in Figure 3, automated treadmill gait analysis
revealed a significant effect of age (F2,77=7.26, p=0.018) and
genotype (F1,77=19.76, p,0.0001) on stride length. Post-hoc
analysis revealed that stride length was significantly reduced in
middle-aged and old Aldh1a1
2/26Aldh2
2/2 mice as compared to
their age-matched wild-type controls. Interaction accounts for
approximately 6.57% of the total variance (F2,77=3.81, p=0.026),
suggesting that stride length might change with age differently in
wild type and Aldh-deficient animals. No significant effects of age
and genotype were observed on stride frequency and stride
duration.
L-DOPAAlleviatedMotorDeficitsinAldh1a1
2/26Aldh2
2/2
Mice
The effect of L-DOPA plus benserazide treatment on rotarod
performance is shown in Figures 4A and 4B. There was a
significant interaction between genotype and age (F1,60=6.73112,
p=0.0119) as well as between genotype and treatment
(F1,61=9.74989, p=0.0027) indicating that the change in rotarod
performance with age and in response to treatment differs
significantly depending on genotype. Data from wild type and
Aldh1a1
2/26Aldh2
2/2 animals were analyzed separately. There
was no significant effect of either age or L-DOPA in wild type
animals but in Aldh1a1
2/26Aldh2
2/2 animals there was a
significant decline in rotarod performance with age
(F1,32=8.03070, p=0.0079) and a significant improvement in
response to L-DOPA (F1,32=17.69678, p=0.0002). The age-
treatment interaction was not significant (F1,32=0.55346,
p=0.4623), indicating that the response to L-DOPA was not
dependent on age. After correcting for the effect of age, the
Aldh1a1
2/26Aldh2
2/2 group had a significantly shorter mean
latency to fall both before (F1,60=26.10433, p,0.0001) and after
(F1,60=5.31982, p=0.0246) L-DOPA treatment.
The effect of L-DOPA plus benserazide on gait analysis is
shown in Figures 4C–E. Automated treadmill gait analysis
revealed a significant interaction between genotype and treatment
Figure 1. Effect of genotype and age on body weight and muscle strength. (A) Body weight and (B) grip strength. Data are expressed as the
mean 6 SEM of the following number of mice of each age and genotype: young (wt=34, ko=35), middle-aged (wt=23, ko=46) and old (wt=25,
ko=29) male mice.
doi:10.1371/journal.pone.0031522.g001
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response to treatment differs significantly depending on genotype.
Data from wild type and Aldh1a1
2/26Aldh2
2/2 animals were
analyzed separately. There was a significant decline in stride
length with age in wild type animals (F1,28=8.5845, p=0.0067)
and no other significant effects. After correcting for the effect of
age, the Aldh1a1
2/26Aldh2
2/2 animals had significantly shorter
rotarod times (F1,60=26.10433, p,0.0001) than wild type without
L-DOPA and when treated with L-DOPA the difference was no
longer significant (F1,59=1.996, p=0.163). Parenthetically, the
Aldh1a1
2/26Aldh2
2/2 animals also had a significantly shorter
stride before L-DOPA treatment (F1,59=7.9885, p=0.0064) but
those measurements were not compared with L-DOPA due to the
confounding effect of adaptation described in the methods.
Effect of Genotype on Cognition
The Y-maze test is a measure of hippocampal-dependent short-
term memory. It is based on the innate preference of animals to
remember and explore an arm that has not been previously
explored. We recorded the percentages of novel arm entries and
spontaneous alternations. As shown in Figure 5A, there was no
significant effect of age (F2,44=2.768, df=2, p=0.074) or
genotype (F1,44=2.013, p=0.163) on total arm entry number.
Figure 5B shows that there was no significant effect of age
(F2,44=0.387, p=0.681) or genotype on novel arm entries
(F1,44=0.182, df=1, p=0.672). However, as shown in
Figure 5C, there was a significant effect of genotype
(F1,44=2.463, df=1, p=0.002) on the percent of alternation in
the old Aldh1a1
2/26Aldh2
2/2 mice, but there was no significant
effect of age (F2,44=1.338, p=0.273). We found a significant
interaction of age and genotype (F2,44=3.159, p=0.05), so it is
possible that there are age-dependent differences in percent
alteration among wild type and Aldh-deficient animals if the
genotypes were to be measured individually. By using one-way
ANOVA followed by Student-Newman-Keuls post-hoc comparison,
we found significant age-related differences (F2,25=4.230,
p=0.026) in old Aldh1a1
2/26Aldh2
2/2 mice compared to
middle-aged (p=0.026) and young (p=0.048) mice. The percent
alternation was not different in different age groups of wild-type
mice (F2,19=0.244, p=0.786). Post-hoc comparison of individual
group means revealed that the oldest Aldh1a1
2/26Aldh2
2/2 mice
had a significant decrease in the mean percentage of alternations
as compared to wild-type controls (Figure 5C), indicating
decreased working memory in the old Aldh1a1
2/26Aldh2
2/2
mice as compared to wild-type control.
Effect of Genotype on Neostriatal Monoamines and
Metabolites
Figure 6 shows the effects of age and genotype on dopamine and
metabolites. As shown in Figure 6A, there was a significant effect
of age (F2,110=5.996, p=0.003) and genotype (F1,110=7.304,
p=0.008) on dopamine content. There was no statistically
significant interaction between genotype and age (F2,110=0.778,
p=0.462). Post-hoc comparison of individual group means
showed a significant (p=0.009) difference in dopamine between
Aldh1a1
2/26Aldh2
2/2 mice and wild-type controls at middle age,
and a marginally significant decrease (p=0.081) in the oldest
group. As shown in Figure 6B, there was a significant effect of
genotype (F1,110=29.991, p=0.001) but not age (F2,110=2.488,
p=0.088) on neostriatal DOPAC content. The difference in the
mean values among the different age groups was not great enough
to exclude the possibility that the difference is due to random
sampling variability after allowing for the effects of differences in
genotype. The interaction of age and genotype (F2,110=0.895,
p=0.412) was not significant. Post-hoc comparison of individual
means revealed significant differences in mean levels of DOPAC
between Aldh1a1
2/26Aldh2
2/2 and wild-type mice at all ages
(Figure 6B). As shown in Figure 6C, there was a significant effect of
genotype (F1,110=5.458, p=0.021) and a marginally significant
effect of age (F2,110=2.975, p=0.055) on HVA content. There
was no statistically significant interaction between genotype and
age (F2,110=0.794, p=0.454). Post-hoc comparison of individual
group mean values for HVA content revealed a significant
difference between Aldh1a1
2/26Aldh2
2/2 mice and the wild-type
controls only in the oldest group.
Figure 7 shows the effects of age and genotype on serotonin (5-
hydroxytryptamine, 5-HT) and its metabolite, 5-hyrdoxy-indole
acetic acid (5-HIAA). Figure 7A shows that there was a significant
effect of genotype (F1,110=8.723, p=0.004) on 5-HT content, but
no significant effect of age (F2,110=0.825, p=0.441). There was no
interaction between age and genotype (F2,110=0.276, p=0.76).
Post-hoc analysis revealed a significant reduction in mean 5-HT
content in Aldh1a1
2/26Aldh2
2/2 mice in the oldest group as
compared to age-matched wild-type mice (p=0.006). Figure 7B
shows that there was a significant effect of age (F2,110=2.234,
p=0.112) and genotype (F1,110=5.817, p=0.018) on 5-HIAA
content. There was no statistically significant interaction between
genotype and age (F2,110=0.3, p=0.741). Post-hoc comparison of
Figure 3. Effect of genotype and age on gait. Data are expressed
as mean 6 SEM of the following number of each age and genotype:
young (wt=8, ko=9), middle-aged (wt=11, ko=14) and old (wt=18,
ko=23) male mice. Asterisks above bars indicate significant difference
between age-matched wt and ko groups. Asterisks above lines indicate
significant difference between indicated means. *P,0.05; **P,0.01;
***P,0.001.
doi:10.1371/journal.pone.0031522.g003
Figure 2. Effect of genotype and age on rotarod performance.
Data are expressed as the mean 6 SEM of measures from the following
number of mice of each age and genotype: young (wt=34, ko=35),
middle-aged (wt=23, ko=46) and old (wt=25, ko=29) male mice.
Asterisks above bars indicate significant difference between age-
matched wt and ko groups. Asterisks above lines indicate significant
difference between indicated means. *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0031522.g002
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Aldh1a1
2/26Aldh2
2/2 mice and the wild-type controls in only
the oldest group (p=0.015).
Effect of Genotype and Age on Aldehyde accumulation
Figure 8 shows striatal content of DOPAL (Figure 8A) and
midbrain 4-HNE-protein adducts (Figures 8B and S2). Striatal
DOPAL was measured by HPLC with electrochemical detection
after batch alumina extraction. A subset of striatal tissue taken
from the opposite side of the brain from those used to measure
monoamines and metabolites was used for DOPAL measurement.
A significant effect of genotype (F1,44=17.243, p,0.001) on
DOPAL level was found; striatal DOPAL was elevated across ages
of the Aldh1a1
2/26Aldh2
2/2 mice. There was no effect of age
(F2,44=0.272, p=0.763) on striatal DOPAL content and no
significant interaction between age and genotype (F2,44=0.007,
p=0.993).
Figure 8B shows that the content of 4-HNE adducted proteins
was elevated in middle age and old Aldh1a1
2/26Aldh2
2/2 mice.
By semi-quantification of western blotting (Figure S2), there was
significant effect of genotype (F1,18=22.874, p,0.001) on the
intensity of 4-HNE-protein adducts in the midbrains of middle age
(p=0.002) and old (p=0.017) Aldh1a1
2/26Aldh2
2/2 mice. No
significant effect of age (F2,18=0.427, p=0.659) nor interaction
between age and genotype (F2,18=0.678, p=0.520) were found on
4-HNE-protein adducts.
Figure 4. L-DOPA alleviated age-related motor deficits in Aldh1a1
2/26Aldh2
2/2 mice. Performance on the accelerating rotarod was
measured in Aldh1a1
2/26Aldh2
2/2 double knockout mice and age-matched wild type controls (A) before and (B) after L-DOPA treatment. Stride
length was measured in Aldh1a1
2/26Aldh2
2/2 double knockout mice and age-matched wild type controls (C) before and (D) after L-DOPA
treatment. Measurement of stride length after elimination of L-DOPA (E) was performed 7 days after L-DOPA injection. Data in all panels are
expressed as mean 6 SEM of the following number of animals in each age group: young (wt=5, ko=6), middle-aged (wt=5, ko=13) and old
(wt=13, ko=16) male mice. Asterisks above bars indicate significant difference between age-matched wt and ko groups. Asterisks above lines
indicate significant difference between indicated means. *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0031522.g004
Figure 5. Effect of age and genotype on Y maze performance. (A) Total arm entries, (B) novel arm entries and (C) percent of arm alternations
were measured in Aldh1a1
2/26Aldh2
2/2 double knockout mice and age-matched wild type controls. Data are expressed as mean 6 SEM of young
(wt=5, ko=7), middle-aged (wt=5, ko=13) and old (wt=13, ko=13) male mice. Asterisks above bars indicate significant difference between age-
matched wt and ko groups. Asterisks above lines indicate significant difference between indicated means. *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0031522.g005
Aldehyde Detoxification and Parkinson’s Disease
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31522Effect of Genotype and Age on the Number of Tyrosine
Hydroxylase (TH) Immunoreactive Neurons in the
Substantia Nigra Pars Compacta (SNpc)
Figure 9 shows the effects of age and genotype on cell
morphometry in the midbrain. Unbiased stereology was used to
estimate the number of dopaminergic neurons in the SNpc
(Figure 9). As shown in Figure 9G, there was a significant effect of
genotype (F1,29=13.054, p,0.001), but not age (F2,29=1.211,
p=0.313) on the number of TH-immunoreactive neurons. There
was no statistically significant interaction between age and
genotype (F2,29=0.089, p=0.915). Post-hoc analysis of differences
between individual means revealed significant 50% and 46%
reductions in TH immunoreactive neurons in the middle-aged and
old Aldh1a1
2/26Aldh2
2/2 mice, as compared to age-matched
wild-type mice. Figure 9H shows that there was no significant
effect of age (F2,29=0.610, p=0.550) or genotype (F1,29=2.051,
p=0.163) on the number of Nissl-stained cells and no statistically
significant interaction between age and genotype (F2,29=0.331,
p=0.721). Figure 9H shows that there was no effect of age
(F2,29=0.708, p=0.505) or genotype (F1,29=0.107, p=0.748) on
the size of TH-immunoreactive neurons and no significant
interaction between age and genotype (F2,29=0.224, p=0.802).
Discussion
Aldehyde accumulation and/or impaired aldehyde detoxifica-
tion has been hypothesized to play a role in the pathogenesis of PD
[6,19–22]. It was recently reported that patients who died with PD
had an elevated DOPAL-to-dopamine ratio in caudate and
Figure 6. Effect of age and genotype on striatal dopamine and metabolites. Dopamine (A), DOPAC (B), HVA (C), DOPAC to DA ratio (D) and
HVA to DA ratio (E) were measured in the neostriatum of Aldh1a1
2/26Aldh2
2/2 double knockout mice and age-matched wild type controls.
Pathways by which dopamine is metabolized to its metabolites are shown in (F). Data are expressed as the mean 6 SEM of young (wt=13, ko=11),
middle-aged (wt=16, ko=20) and old (wt=23, ko=32) male mice. Asterisks above bars indicate significant difference between age-matched wt and
ko groups. Asterisks above lines indicate significant difference between indicated means. *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0031522.g006
Figure 7. Effect of age and genotype on striatal 5-HT and 5-HIAA. The level of serotonin (A) and its metabolite, 5-HIAA (B) were measured in
Aldh1a1
2/26Aldh2
2/2 mice and age-matched wild type controls. Pathways by which 5HT is metabolized to its metabolites are shown in (C). Data are
expressed as the mean 6 SEM of the following number of wild-type and knockout mice in each age group: young (wt=13, ko=11), middle-aged
(wt=16, ko=20) and old (wt=23, ko=32) male mice. *P,0.05, significantly different from age-matched wild-type control group. **P,0.01,
significantly different from age-matched wild-type control group.
doi:10.1371/journal.pone.0031522.g007
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highly reactive and can modify proteins [6–9]. Aldehydes are also
cytotoxic and have been demonstrated to kill dopaminergic cells in
vitro and after intracranial injection [20,21,23–26]. A loss of
function polymorphism in ALDH2 has been reported to be a risk
factor for Alzheimer’s disease [16,18,27]. Others have reported
that ALDH1A1 mRNA is reduced in substantia nigra dopaminer-
gic neurons in brains of PD patients [15] and ALDH1A1
expression level in peripheral tissues has been reported as a
candidate biomarker for PD diagnosis [28]. These findings are
strongly suggestive of a role for reduced aldehyde detoxification in
the development of neurodegenerative diseases. However, until
now, direct evidence for a causal relationship between impaired
aldehyde detoxification and neurodegeneration in PD has been
lacking. We hypothesized that chronically decreased function of
multiple aldehyde dehydrogenases consequent to impaired
complex I, and/or reduced ALDH expression, plays a role in the
pathophysiology of PD. To test this hypothesis, we generated a
mouse model null for both Aldh1a1 and Aldh2, the two isoforms of
aldehyde dehydrogenase that are known to be expressed in
midbrain dopaminergic neurons [13–15]. The results show that
mutations in these two aldehyde dehydrogenase isoforms resulted
in neurochemical evidence for ALDH inhibition and elevated
striatal tissue DOPAL, followed by aging-related development of a
PD-like phenotype.
Mice deficient in Aldh1a1 and Aldh2 exhibited age-related
deficits in tests of motor performance that require a high degree of
motor coordination. We found progressive age-related impairment
in rotarod performance in the Aldh1a1
2/26Aldh2
2/2 mice as
compared to wild-type controls. These effects were not due to
alterations in muscle strength, body weight, motor learning, visual
impairment or changes in circadian patterns of activity, factors
that may confound the interpretation of rotarod performance [29].
This impairment in rotarod performance is consistent with what
others have observed in animal models of PD. Rotarod
performance has been shown to be impaired in genetic [30,31]
and toxin-induced [32] animal models of PD.
Altered gait pattern is symptomatic of PD [33–35]. A behavioral
hallmark of PD is a shortened stride length, which is manifested as
a shuffling gait [34,35]. Alterations in gait have also been observed
in animal models of PD and in models of other basal ganglia
diseases, including Huntington’s disease [36–38]. Conversely,
others have reported that gait analysis did not detect alterations in
the MPTP model of PD or in a model of amyotrophic lateral
sclerosis [39]. In the present study, gait analysis revealed
a significant 8.3% reduction of stride length in the oldest
Aldh1a1
2/26Aldh2
2/2 mice. A similar magnitude of reduction
in stride-length was reported for mice treated with MPTP [40].
That paper also reported a similar shorter stride duration and
stride frequency [40]. We found no differences in stride duration
and frequency. On the other hand, others have reported no
differences in stride length, but shorter stride duration and
frequency in mice overexpressing human a-synuclein [41]. Unlike
MPTP-treated mice, those mice showed no loss of dopamine
neurons. Thus, gait parameters may be differentially affected by
the underlying pathology.
Responsiveness to L-DOPA treatment is diagnostic of PD
[42,43]. To test whether Aldh1a1
2/26Aldh2
2/2 mice were
responsive to L-DOPA treatment, we treated mice with L-DOPA
plus benserazide, a peripheral aromatic amino acid decarboxylase
inhibitor. The dose that we used (25 mg/kg body weight) was
chosen based on calculations of the human equivalent dose
(,2.03 mg/kg) as reported by FDA Draft Guidelines [44,45]. This
dosage is also one that is commonly reported for mice in the
literature [46,47]. L-DOPA treatment did not alter rotarod or gait
performance of wild-type mice as compared to the baseline
measurements. However, L-DOPA treatment alleviated the age-
related deficits in stride length and rotarod performance in
Aldh1a1/Aldh2-deficient mice. Furthermore, deficits in stride
length reappeared a week after L-DOPA treatment, a time when
L-DOPA had been completely eliminated. Thus, with respect to
responsiveness to L-DOPA, the Aldh1a1/Aldh2-deficient mice
model this aspect of Parkinson’s disease. One might argue that
L-DOPA administration would enhance aldehyde accumulation
and toxicity and thus impair performance in Aldh1a1/Aldh2-
deficient mice. However, we feel that it is unlikely that a single L-
DOPA injection would cause immediate and measureable
cytotoxicity and/or augmentation of dopaminergic neurodegen-
eration.
Cognitive impairment is often found in PD [48]. For example,
patients with mild, early stage, Parkinson’s disease are impaired in
planning and spatial working memory tests [49]. Therefore, we
measured cognitive function by a Y-maze test, an assessment of
short-term spatial working memory that is based on the innate
tendency of rodents to explore novel environments. The
advantage of the Y-maze test is that it is not as dependent on
motor function as compared to other tests of memory, such as the
Morris water maze [50]. The Y-maze paradigm is also less stressful
and less influenced by emotionality [51]. In the present study,
there were no differences due to genotype or age in total or novel
Figure 8. Effect of age and genotype on aldehyde accumulation in the nigrostriatal pathway. (A) Striatal DOPAL measured in the
neostriatum of Aldh1a1
2/26Aldh2
2/2 double knockout mice and age-matched wild type controls. Data are expressed as mean 6 SEM of young
(wt=5, ko=7), middle-aged (wt=5, ko=9) and old (wt=10, ko=14) male mice. (B) Measurement of 4-HNE-protein adducts in midbrain of Aldh1a1
2/
26Aldh2
2/2 double knockout mice and age-matched wild type controls. n=4 per group. Data expressed as mean 6 SEM. *P,0.05, significantly
different from age-matched wild-type control group. **P,0.01, significantly different from age-matched wild-type control group.
doi:10.1371/journal.pone.0031522.g008
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respectively. However, there was a significant effect of age and
genotype on the percentage of arm alternations, a measure
of spatial working memory. Thus, at the oldest age, the
Aldh1a1
2/26Aldh2
2/2 mice were significantly impaired as
compared to wild-type mice. Deficiency in short-term spatial
working memory, as measured in a T-maze, has been previously
reported in mice treated with moderate doses of MPTP to mimic
early stage PD [52]. In that study, the dose used produced a 50 to
60% decrease in dopamine, but had no effect on locomotor
activity in an open field test, similar to the levels of impairment in
these parameters that we observed in our model in the present
study. Similar effects of low dose MPTP on spatial working
memory have been reported in monkeys [53]. Thus, the effects of
age and Aldh1a1/Aldh2-deficiency on spatial memory recapitulate
the cognitive deficits seen in early stage Parkinson’s disease.
We also measured monoamines and metabolites in the
neostriatum. The serotonergic system has been reported to be
affected in PD patients, although to a smaller extent than the
dopaminergic system [54]. Reductions in serotonin and its
metabolite 5-HIAA in caudate nucleus and putamen of PD
patients have been reported [55,56]. Several studies have linked
complications found in PD, such as fatigue, depression and
dementia, to dysfunction of the serotonergic system [1,57,58].
Figure 9. Effect of age and genotype on the number of dopamine neurons in the substantia nigra. (A–F) Representative coronal sections
from Aldh1a1
2/26Aldh2
2/2 mice and age-matched wild type controls showing regions of substantia nigra pars compacta (SNpc) selected for TH+
cell counts. Quantification data of (G) TH+ neurons, (H) Nissl cells, and (I) TH+ cell volume are expressed as the mean 6 SEM of the following number
of mice in each group: young (wt=4, ko=3), middle-aged (wt=5, ko=5) and old (wt=5, ko=9) male mice. *P,0.05, significantly different from age-
matched wild-type control group.
doi:10.1371/journal.pone.0031522.g009
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2/26Aldh2
2/2 double
knockout mice exhibited decreased striatal 5-HT (by 39%) and its
metabolite 5-HIAA (by 38%), only at the oldest age.
Deficiency in Aldh1a1 and Aldh2 was also associated with
significant decreases in dopamine and its metabolites DOPAC and
HVA in middle aged and old mice. The deficits in dopamine and
HVA content were only significant in the middle-aged and oldest
group, respectively. In contrast, DOPAC was reduced by 48 to
67% of control at all ages and DOPAL was increased at all ages.
The deficiency in DOPAC and the increase in DOPAL is
consistent with the idea that Aldh1a1 and/or Aldh2 play a role in
metabolism of DOPAL to DOPAC. We previously reported that
deficiency in Aldh2 was not associated with alterations in dopamine
or metabolites [59]. Recently, it was reported that in Aldh1a1
deficient mice 2–3 months of age, there was no reduction in
striatal dopamine levels and that DOPAC was slightly but
significantly reduced by 20% as compared to wild-type control
mice [60]. The up to 67% reduction in DOPAC in the present
study, as compared to the much smaller reduction in the Aldh1a1-
deficient mice reported previously [60], supports the idea that
more than one aldehyde dehydrogenase participates in metabo-
lizing DOPAL to DOPAC. A recent clinical study reported that
DOPAL-to-dopamine ratio was significantly elevated in the
caudate and putamen of PD patients [11]. The reduced ability
to detoxify DOPAL by metabolizing it to DOPAC may contribute
to the degeneration of dopamine neurons in PD. Thus, in the
present study, elevated striatal DOPAL preceded evidence of loss
of dopaminergic terminals.
In addition to the elevated DOPAL content, we observed
increases in 4-HNE adducted proteins in the midbrain. Together,
these results provide direct evidence that Aldh1a1 and Aldh2 are
necessary to detoxify multiple biogenic aldehydes. Since each of
these is known to be cytotoxic, this suggests that accumulation of
multiple biogenic aldehydes may contribute to the neurodegen-
eration observed in PD. Thus, DOPAL and 4-HNE have been
reported to induce death of cultured cells [22,61]. Moreover,
DOPAL has been reported to cause degeneration of dopaminer-
gic neurons when injected intracranially [20]. In addition,
DOPAL and 4-HNE have been reported to accelerate oligomer-
ization of a-synuclein and such oligomers may also be cytotoxic
[8,9].
A loss of TH-immunoreactive cells was observed in
Aldh1a1
2/26Aldh2
2/2 mice. A statistically significant reduction
of up to 50% was observed in middle-aged and old
Aldh1a1
2/26Aldh2
2/2 mice as compared to their age-matched
wild-type controls. The loss of TH-immunoreactive neurons is
consistent with the loss of striatal dopamine. However, the loss of
striatal dopamine was smaller in magnitude than the reduction in
TH-immunoreactive neurons. It has long been reported that in
studies of post-mortem human brain tissue, the degree of loss of
substantia nigra dopamine neurons is greater than the loss of
dopamine and metabolites in striatal regions, suggesting that
surviving neurons have an increased capacity to make and store
dopamine [62]. There was no significant difference in the number
of Nissl-stained cells, indicating that the reduction in TH
+ neurons
was relatively specific. There was also no difference in the size of
the TH
+ cells. There is no preclinical or clinical evidence showing
a relationship between Aldh2 deficiency and neurochemical and
behavioral manifestations of PD. However, the loss of TH
+ cells in
the Aldh1a1
2/26Aldh2
2/2 mice is in contrast to a recent report
that TH
+ neurons are increased in Aldh1a1-deficient mice [60].
Taken together, these findings suggest that deficiency in only one
aldehyde dehydrogenase isoform is insufficient to cause neuropa-
thology and that multiple redundant mechanisms for aldehyde
detoxification participate in protecting dopamine neurons from
the toxic effects of aldehydes.
In summary, deletion of two isoforms of aldehyde dehydroge-
nase, Aldh1a1 and Aldh2, which are known to be present in
dopamine neurons, resulted in a Parkinsonian phenotype
characterized by age-dependent deficits in motor performance,
age-related reductions in monoamines and their metabolites and
loss of neurons in the substantia nigra. These results provide the
first direct support for the hypothesis that impaired aldehyde
detoxification plays a role in PD. The Aldh1a1
2/26Aldh2
2/2
mouse may be a useful new model of early stage Parkinson’s
disease.
Materials and Methods
Animals and Ethics Statement
Animals were maintained, and experiments were conducted, in
strict accordance with the Institutional Animal Care and Use Committee
(IACUC), The University of Texas Health Science Center at San Antonio
and the South Texas Veterans Health Care System (San Antonio, TX),
and with the 1996 Guide for the Care and Use of Laboratory Animals
(Institute of Laboratory Animal Resources on Life Sciences, National Research
Council, National Academy of Sciences). All protocols were designed to
minimize animal discomfort. Animals were group housed with five
per cage in ventilated cages that were maintained at an ambient
temperature of 23–25uC and on a 12-hour light-dark cycle.
Rodent bedding consisted of Sani-Chips (Harlan Teklad, Madi-
son, WI). Mice had free access to food (Teklad 7912, Rodent
sterilized diet, Harlan Teklad, Madison, WI) and water. The
Aldh1a1
2/26Aldh2
2/2 mice used in this study were generated by
crossing mice with a targeted mutation in Aldh1a1 with a line of
mice carrying a mutation in Aldh2. Mice null for Aldh2 were
generated by gene trap mutagenesis as we have previously
reported [59] and were backcrossed to C57BL/6J mice for 10
generations. The Aldh1a1 mutant mice were generated by Gregg
Duester and colleagues using a targeted deletion at exon 11 of the
Aldh1a1 allele [63] and were backcrossed by us for 8 generations to
C57BL/6J. Aldh1a1
2/2 mice were crossed with Aldh2
2/2 mice to
produce mice heterozygous for both genes, Aldh1a1
+/26Aldh2
+/2.
Cross-breeding of Aldh1a1
+/26Aldh2
+/2 generated the
Aldh1a1
2/26Aldh2
2/2 line and the wild type Aldh1a1
+/+6Aldh2
+/+
line. The two lines were maintained by breeding male and female
Aldh1a1
2/26Aldh2
2/2 or Aldh1a1
+/+6Aldh2
+/+ mice. Male mice of
three different age groups (young, 5–8 months; middle-aged, 12–14
months; and old, 18–27 months), were used for the study. Body
weights were monitored prior to and during behavioral testing.
Treatments and behavioral tests were blinded, randomly assigned,
and performed during the light cycle from 8am to 6pm if not
otherwise indicated.
Grip Strength
Mice were allowed to grip the metal grids of a grip meter
(Ametek Chatillon) with their forepaws, and they were gently
pulled backwards by the tail until they could no longer hold the
grids. The peak grip strength observed in 5 trials was recorded.
Open Field Activity and 24-hour Locomotor Activity
For open field activity, mice were placed in an open field arena
(40640640 cm); for 24-hour locomotor recording, mice were
placed in plastic boxes (48624620 cm) and interruptions of the
photo-beams were recorded and analyzed using compatible
computer software. Data were collected for 30 min and assessed
at five-min intervals for locomotor activity. For 24-hour activity,
each test session started at 5 pm and ended at 6 pm the next day
Aldehyde Detoxification and Parkinson’s Disease
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one-hour intervals.
Accelerating Rotarod Performance
Mice were trained on the rotarod for two days and then tested
on the third day. Three trials were performed on each day. During
each trial, the rotarod began at an initial speed of 4 rpm and then
increased gradually to 40 rpm within 300 seconds. The averaged
latency to fall from the accelerating rod was calculated from the
three trials performed on the third day.
Automated Gait Analysis
Animals were tested on the ExerGait (Columbus Instruments)
treadmill at a speed of 15 cm/sec for 10 sec. A digital camera
recorded the reflected images of the footpads. The digital camera
was operated at 80 frames per second and the output was fed
directly to computer. Video recordings were analyzed by
TreadScan
TM 1.0 software (Clever Sys Inc.). The average of each
parameter was collected from the strides within a 20–100 mm
range.
Y-maze Test
To measure the effect of genotype on cognitive performance,
mice were tested in a three-armed Y-maze test. Mice were pre-
trained with one arm blocked (i.e., arm C) and allowed to move
freely in the other two arms. The percentage of the triads in which
all three arms were represented (ABC, CAB, or BCA but not BAB)
were recorded on the 5-min testing trial.
L-DOPA Drug Administration
After baseline measures of gait and rotarod performance,
animals received 25 mg/kg L-DOPA (Sigma) administered
concurrently with 12.5 mg/kg benserazide intraperitoneally.
Motor function was assessed within the 30–120 min peak
therapeutic window for L-DOPA.
Preparation of Brain Tissue
Brains were rapidly collected by decapitation following brief
CO2 inhalation. For neurochemical assays, brain tissue was
rapidly dissected on an ice-cold platform; tissue was then snap-
frozen on dry ice and transferred to a 280uC freezer for storage.
Samples were homogenized in ice-cold 0.1 M perchloric acid
(HClO4) for HPLC analysis or in NP-40 lysis buffer (Fluka) for
Western blotting protein extraction. Brain samples for immuno-
histochemical analyses were removed, subsequently stored over-
night in 4% paraformaldehyde (PFA; Affymetrix) at 4uC and then
cryoprotected in 30% sucrose. A cryostat was used to cut serial
40 mm coronal sections through the midbrain and then stored in a
cryopreservative buffer consisting of 30% glycerol/30% ethylene
glycol in 100 mM sodium phosphate at 220uC.
Measurement of Monoamine and Metabolites
Samples were homogenized in ice-cold 0.1 M HClO4 contain-
ing 10 ng/mL DHBA (3,4-dihydroxybenzylamine) as the internal
standard and centrifuged to remove precipitated proteins. The
supernatants were used for HPLC analysis. An aliquot of the
supernatant was filtered through a 0.45-mm microcentrifuge filter
(Millipore). Dopamine, serotonin, and metabolites were separated
using a high-performance liquid chromatography (HPLC, ESA)
system with an HR-80 reverse-phase C18 column (4.6680 mm).
Samples were detected with an electrochemical detector (ECD) on
a dual-electrode analytical cell (Model 5011A). The pH of the 6%
acetonitrile (v/v) mobile phase was adjusted to pH 3.11 with
phosphoric acid after the addition of organic modifiers. The flow
rate of mobile phase was set at 1.0 mL/min.
Measurement of the aldehyde intermediate of dopamine
metabolism, DOPAL
DOPAL was measured at the Catecholamine Resource Unit of
the Clinical Neurocardiology Section of the NINDS, according to
a previously described method [11]. Samples were homogenized
in an acid solution containing 20 : 80 parts of 0.2 M acetic acid
and phosphoric acid solution. After homogenization, samples were
centrifuged and the supernatant was frozen and stored at 280uC
freezer for storage until assayed for DOPAL by HPLC with
electrochemical detection after batch alumina extraction. Briefly,
mobile phase containing octanesulfonic acid as an ion pairing
agent was pumped isocratically through a reverse phase liquid
chromatographic column. Catechols were quantified by the
current produced upon exposure of the eluate to flow-through
electrodes set to oxidizing and then reducing potentials in series,
with recording from the last electrode reflecting reversibly oxidized
species.
Measurement of 4-HNE-protein adducts
Midbrains were homogenized in NP-40 lysis buffer (Fluka).
Protein concentrations were determined using the Bradford assay
(Bio-Rad, Hercules, CA, USA) following the manufacturer’s
instructions. Total protein of 40 mg per sample were subjected to
4–11% SDS-PAGE (Bio-Rad; sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis). Separated proteins were then trans-
ferred onto a nitrocellulose membrane (0.45 mm, PROTRAN,
Whatman) using 20% methanol wet transfer for immunostaining.
The membrane was blocked for 1 hour in Odyssey blocking
solution (LI-COR). Content of 4-HNE-protein adducts (R&D,
1:1,000) was analyzed by an Odyssey IR scanner (LI-COR) with
appropriate secondary IRDye (LI-COR) antibody.
TH Immunohistochemistry
Free floating sections were washed with 16phosphate-buffered
saline (PBS), and endogenous peroxidases were quenched by 1%
hydrogen peroxide for 10 minutes at room temperature (RT),
followed by rinses with 16PBS. After sections were blocked with
1% Bovine serum albumin, 3% normal goat serum and 0.3%
TritonX-100, they were stained with rabbit anti-TH (1:1000; Pel-
Freeze) for 48 hours at 4uC. Following primary incubation,
sections were washed with 16PBS and incubated in biotinylated
anti-rabbit secondary antibody (1: 400; Vector Laboratories) with
blocking buffer for 60 minutes at RT. Afterward, sections were
washed with 16 PBS and then re-incubated in ABC solution
(Vectastain ABC kit; Vector Laboratories) for 30 minutes at RT.
For color development, sections were treated with 3-diaminoben-
zidine (DAB) as the chromogen with nickel chloride amplification.
Finally, sections were mounted on positively charged slides,
counterstained with 0.1% cresyl violet (Nissl staining) and cover-
slipped.
Measurement of Midbrain Dopamine Neurons by
Unbiased Stereology
Unbiased stereology methodology was used to estimate the
number of tyrosine hydroxylase positive (TH
+) and Nissl-stained
(Nissl
+) cells in the SNpc. Cells were visualized by a Nikon
microscope, and images were relayed via a MicroFibre digital
camera (http://www.optronics.com) to a computer where they
were counted by a blinded observer using the optical fractionator
the Stereologer system (Stereology Resource Center, Chester,
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beginning at bregma – 2.06 mm and finishing at bregma –
4.16 mm. Sections were cut at a thickness of 40 mm to allow an
average of 18 mm thick optical dissector within each section after
staining and dehydration processes. Reference spaces on each
section were outlined under low magnification (46), and TH
+ and
Nissl
+ neurons were counted at high magnification (406), with a
guard volume of 1 mm on both surfaces to avoid artifacts on the
cut surface of sections. The first sample section from the first 1–6
sections collected was chosen at random. TH
+ cells were counted
in grids randomly positioned by the software in the outlined
counting area through all optical planes, thus creating a three-
dimensional counting area. The counting criteria included the
presence of TH immunoreactivity in the cytoplasm of cells with a
neuronal phenotype, including a clear nuclear membrane and
distinct nucleolus. We also used an additional stereological probe,
the rotator method, to measure cell volume.
Statistical Analysis
Significance of the effects of age and genotype was determined
by two-way ANOVA with age and genotype as factors. Differences
between individual means were assessed by the Student-Newman-
Keuls post-hoc comparison to assess differences between individual
means. For experiments involving multiple measures to analyze
the effect of L-DOPA administration on gait and rotarod
performance, a mixed-effect ANCOVA model with first order
interactions was fitted to the data. Genotype and L-DOPA were
used as categorical variables, age as a numeric variable, and
different animals as a grouping variable. Likelihood ratio tests
were used to determine which random effects to include. For
rotarod, random-intercept and random-slope terms were included
in the model and for gait, only a random-intercept term was
necessary. When there were significant interactions involving
genotype, data from the wild type and Aldh-deficient were
analyzed separately using a reduced version of the above model.
To determine the effect of genotype alone while taking into
consideration the effect of age, a one-way mixed-effect ANOVA
with random intercepts and age as a grouping variable was fitted
separately to baseline and L-DOPA data. In the case of gait
analysis, to correct for adaptation to the apparatus, performance
after a one-week post L-DOPA washout period was used as the
baseline measurement rather than the initial pre L-DOPA
measurement. For the mixed-model analysis, the R statistical
language [64] with the nlme package [65] were used.
Supporting Information
Figure S1 Effect of Aldh1a1
2/26Aldh2
2/2 genotype on
locomotor activity. (A) General locomotor activity measured in
an open field, (B) light/dark open field activity test and (C) 24-hour
activity tests. Data are expressed as the mean 6 SEM of the
number of wild type and knockout mice in the following age-
groups: young (wt=5, ko=7), mid-aged (wt=11, ko=12) and old
(wt=7, ko=9) male mice.
(TIF)
Figure S2 Effect of age and genotype on midbrain 4-
HNE-protein adducts. Figure S2 shows the western blot of 4-
HNE-adducts in midbrains of Aldh1a1
2/26Aldh2
2/2 mice and
age-matched wild type controls. Integrated intensity was measured
using Odyssey IR scanner (LI-COR). An integrated density ratio
was calculated from the intensity of the whole lane of 4-HNE-
adducted proteins divided by the intensity of the GAPDH band
corrected for background. Background was obtained from the top
and bottom of each lane.
(TIF)
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